ZOETIS INC. (ZTS) is a publicly traded Healthcare sector company. As of July 5, 2026, ZTS trades at $74.80 with a market cap of $31.36B and a P/E ratio of 12.38. ZTS moved +4.33% today. Year to date, ZTS is -40.83%; over the trailing twelve months it is -52.98%. Its 52-week range spans $71.47 to $181.85. Analyst consensus is buy with an average price target of $114.14. Rallies surfaces ZTS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Analyst Sees Zoetis Product Stabilization Delayed by Several Quarters: An analyst warns Zoetis will not see stabilization in product supply and pricing until several quarters from now, delaying margin improvement expectations. This outlook indicates revenue growth may remain pressured for the next few fiscal periods as market conditions normalize slowly.
| Metric | Value |
|---|---|
| Price | $74.80 |
| Market Cap | $31.36B |
| P/E Ratio | 12.38 |
| EPS | $6.04 |
| Dividend Yield | 0.53% |
| 52-Week High | $181.85 |
| 52-Week Low | $71.47 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $9.51B |
| Net Income | $2.64B |
| Gross Margin | 71.76% |
10 analysts cover ZTS: 0 strong buy, 5 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $114.14.